NEW DELHI, Iune 22 (Xinhua) - Ua hōʻike ʻo Covaxin ʻo Bharat Biotech's Covaxin i ka hana kano ma India i ka 77.8 pākēneka i ka hopena i nā hoʻokolohua pae III, ua hōʻike ʻia e ka lehulehu media ma ka Pōʻalua.
"He 77.8 pakeneka ka maikaʻi o ka Bharat Biotech's Covaxin i ka pale ʻana i ka COVID-19, e like me ka ʻikepili mai nā hoʻokolohua pae III i hana ʻia ma 25,800 mau mea komo ma India," wahi a kahi hōʻike.
Ua puka mai ka nui o ka pono ma ka Poalua ma hope o ka hui ʻana o ke komite loea kumuhana (SEC) o ka Drugs Controller General of India (DCGI) a kūkākūkā i nā hopena.
Ua hoʻouna ka ʻoihana lāʻau lapaʻau i ka ʻikepili hoʻāʻo i ka pae III no ke kano i ka DCGI i ka hopena pule.
Ua ʻōlelo ʻo Reports e manaʻo ʻia ka hui e hoʻopaʻa i kahi hālāwai "pre-submission" me nā luna o ka World Health Organization i ka Pōʻakolu, e kūkākūkā i nā alakaʻi no ka hoʻouna hope ʻana i nā ʻikepili i koi ʻia a me nā palapala.
Ua hoʻomaka ʻo India i ka lāʻau lapaʻau nui e kūʻē iā COVID-19 ma Ianuali 16 ma o ka lawelawe ʻana i ʻelua mau maʻi i hana ʻia ma India, ʻo ia hoʻi ʻo Covishield a me Covaxin.
Ke hana nei ka Serum Institute of India (SII) i ka AstraZeneca-Oxford University's Covishield, aʻo Bharat Biotech i hui pū me ka Indian Council of Medical Research (ICMR) i ka hana ʻana iā Covaxin.
Ua ʻōwili pū ʻia ka maʻi Sputnik V i hana ʻia e Rūsia ma ka ʻāina. Hoʻopau
Ka manawa hoʻouna: Iune-25-2021